沙美特罗丙酸氟替卡松吸入治疗稳定期慢性阻塞性肺疾病患者的临床效果研究

Research on Clinical Effect of Salmeterol-fluticasone Inhalation Treating Patients with Chronic Obstructive Pulmonary Disease in Stationary Phase

目的分析沙美特罗丙酸氟替卡松吸入治疗稳定期慢性阻塞性肺疾病患者的临床效果。方法随机选取2013年2月—2016年5月期间慢性阻塞性肺疾病患者60例为研究对象,按照随机数字法将其分为对照组(多索茶碱片+沙丁胺醇气雾剂),实验组(沙美特罗丙酸氟替卡松吸入),各30例;比较两组患者治疗效果。结果实验组总有效率为96.7%,显著高于对照组的总有效率86.7%(P<0.05);对照组的FEV1、FEV1、FEV1/FVC分别为(58.3±7.2)%、(1.5±0.3)L、(61.4±7.3)%显著低于实验组的(52.1±6.2)%、(1.9±0.4)L、(53.3±7.1)%(P<0.05);实验组的Pa CO_2、Pa O_2分别为(42.3±2.4)mm Hg、(78.5±3.5)mm Hg;显著优于对照组的(53.8±3.2)mm Hg、(62.1±4.5)mm Hg(P<0.05)。结论对慢性阻塞性肺疾病患者实施沙美特罗丙酸氟替卡松吸入治疗,能够改善患者的肺功能,提高患者的治疗效果,因此值得在临床上推广。

Objective To analyze the sand meetall fluticasone Luo Bing inhalation therapy period clinical effect of patients with chronic obstructive pulmonary disease. Methods Random selection February 2013 to May 2016, 60 patients with chronic obstructive pulmonary disease as the research object, according to the method of random Numbers will be divided into control group（doxofylline ＋ salbutamol aerosol）, the experimental group（sand meetall fluticasone Luo Bing suction）, 30cases; Compare two groups of patients with therapeutic effect. Results The total effective rate was 96.7%, significantly higher than that of control group total effectiveness 86.7%（P〈0.05）; Control group of FEV1, FEV1, FEV1/FVC were（58.3 ±7.2）%,（1.5±0.3）L,（61.4 ±7.3）% was significantly lower than that of the experimental group of（52.1±6.2）%,（1.9±0.4）L,（53.3±7.1）%（P〈0.05）; The experimental Pa CO_2, Pa O_2were（42.3 ± 2.4） mm Hg,（78.5 ± 3.5） mm Hg;（53.8 ± 3.2）mm Hg significantly better than that of control group（62.1 ± 4.5）mm Hg（P〈0.05）. Conclusion For patients with chronic obstructive pulmonary disease sand meetall fluticasone Luo Bing inhalation therapy, can improve the patient＇s lung function, improve the therapeutic effect of patients, thus is worth popularizing in clinic.